Vibativ approved for certain bacterial pneumonia

(HealthDay)—The antibiotic Vibativ (telavancin) has been approved by the U.S. Food and Drug Administration to treat pneumonia caused by Staphylococcus aureus bacteria when other treatments aren't suitable.

Pneumonia, a , can be caused by different bacteria and viruses. S. aureus infection often affects people in hospitals, notably those on ventilators. Such infections can be serious, since people on a ventilator often have a and are unable to fight an infection, the FDA said in a news release.

Vibativ's safety and effectiveness were evaluated clinically among 1,532 people. The studies found the drug was about as effective in treating S. aureus pneumonia as another approved antibiotic, vancomycin.

However, the studies found that more people treated with Vibativ died if they also had kidney problems, compared to who took vancomycin. The FDA said it would add this information to Vibativ's label. The most common clinical side effect of Vibativ is diarrhea.

Vibativ was first approved in 2009 to treat skin infections. The drug is marketed by San Francisco-based Theravance Inc.

More information: The FDA has more about this approval.

add to favorites email to friend print save as pdf

Related Stories

Less commonly prescribed antibiotic may be better

Aug 16, 2012

The antibiotic most commonly prescribed to treat bloodstream infections in dialysis patients may not always be the best choice, according to a study appearing in an upcoming issue of the Journal of the American Society of ...

Simponi approved for ulcerative colitis

May 15, 2013

(HealthDay)—Simponi (golimumab) injection has been approved by the U.S. Food and Drug Administration to treat adults with moderate-to-severe ulcerative colitis.

Recommended for you

Expression of privilege in vaccine refusal

15 hours ago

Not all students returning to school this month will be up to date on their vaccinations. A new study conducted by Jennifer Reich, a researcher at the University of Colorado Denver, shows that the reasons why children may ...

Using computers to design drugs

Aug 22, 2014

Designing a new medicine is an expensive and time consuming business. Typically it takes around $2 billion and ten years for a new drug to move from its initial design in the lab, to the clinic. All the ...

Lilly psoriasis drug fares well in late-stage test

Aug 22, 2014

Drugmaker Eli Lilly and Co. said its potential psoriasis treatment fared better than both a fake drug and a competitor's product during late-stage testing on patients with the most common form of the skin disease.

User comments